↓ Skip to main content

Dove Medical Press

Article Metrics

Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, May 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
25 Mendeley
Title
Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes
Published in
International Journal of Chronic Obstructive Pulmonary Disease, May 2015
DOI 10.2147/copd.s79710
Pubmed ID
Authors

Jianqing Zhang, Jiaqiang Zhang, Hua Liu, Zhihuan Zhao, Lizhou Fang, Ling Liu, Weiping Fu, Jingkui Shu, Luming Dai, Jia-Gang Feng

Abstract

The role of the antioxidant N-acetylcysteine (NAC) in the treatment of chronic obstructive pulmonary disease (COPD) has not been clarified as yet. In early studies, we found that the proportion of smokers with COPD having extremely slow/slow microsomal epoxide hydrolase (EPHX1) enzyme activity is significantly higher than that in healthy smokers. The purpose of this study was to evaluate whether different EPHX1 enzyme activity is related to differential therapeutic effects of treatment with NAC in COPD. A total of 219 patients with COPD were randomly allocated to an extremely slow/slow EPHX1 enzyme activity group (n=157) or a fast/normal EPHX1 enzyme activity group (n=62) according to their EPHX1 enzyme activity. Both groups were treated with NAC 600 mg twice daily for one year. The main study parameters, including forced expiratory volume in one second (FEV1), St George's Respiratory Questionnaire (SGRQ), and yearly exacerbation rate, were measured at baseline and at 6-month intervals for one year. Both FEV1 and SGRQ symptom scores were improved after treatment with NAC in the slow activity group when compared with the fast activity group. Further, changes in FEV1 and SGRQ symptom score in patients with mild-to-moderate COPD were more significant than those in patients with severe-to-very severe COPD. The yearly exacerbation rates were reduced in both groups, but the reduction in the slow activity group was significantly lower than in the fast activity group. NAC treatment in COPD patients with extremely slow/slow EPHX1 enzyme activity improves FEV1 and the SGRQ symptom score, especially in those with mild-to-moderate COPD, and polymorphism in the EPHX1 gene may have a significant role in differential responses to treatment with NAC in patients with COPD.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 4%
Brazil 1 4%
Unknown 23 92%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 24%
Student > Bachelor 4 16%
Lecturer 3 12%
Other 2 8%
Student > Postgraduate 2 8%
Other 3 12%
Unknown 5 20%
Readers by discipline Count As %
Medicine and Dentistry 13 52%
Pharmacology, Toxicology and Pharmaceutical Science 3 12%
Agricultural and Biological Sciences 1 4%
Nursing and Health Professions 1 4%
Economics, Econometrics and Finance 1 4%
Other 1 4%
Unknown 5 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 May 2015.
All research outputs
#3,577,035
of 5,094,641 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#439
of 623 outputs
Outputs of similar age
#117,710
of 163,282 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#27
of 32 outputs
Altmetric has tracked 5,094,641 research outputs across all sources so far. This one is in the 16th percentile – i.e., 16% of other outputs scored the same or lower than it.
So far Altmetric has tracked 623 research outputs from this source. They receive a mean Attention Score of 3.2. This one is in the 9th percentile – i.e., 9% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,282 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one is in the 3rd percentile – i.e., 3% of its contemporaries scored the same or lower than it.